PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6876439

[252Cf brachytherapy].

T Sugiyama·K Kaneta
View original source ↗Export metadata ↓

Abstract

Value of Californium 252 brachytherapy was discussed from our experience of 117 cases treated with either mold, interstitial or intracavitary application. Differentiated adenocarcinomas, malignant melanomas or recurrent cancers occurred in anoxic scar tissues were considered to be treated more effectively by Californium 252 fast neutron than photon radiation. Optimum absorbed neutron dose was 12-18 Gy. It should be modified depending on condition of surrounding normal tissue, because normal tissue tolerance limits to fast neutron may not be the same as photon radiation.

Explore related subjects

BrachytherapyCaliforniumFemaleHumansMelanomaMouth FloorMouth NeoplasmsPalateSkin NeoplasmsTongue NeoplasmsUterine Cervical NeoplasmsEnglish AbstractJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Sugiyama, K Kaneta. 1983. [252Cf brachytherapy].. https://pubmed.ncbi.nlm.nih.gov/6876439/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.

PURPOSE: To characterize the time to metabolic atrophy (TMA) after permanent prostate implantation (PPI) using combined MRI and magnetic resonance spectroscopic imaging (MRSI) compared with the time to prostate-specific antigen (PSA) nadir. METHODS AND MATERIALS: This study was based on a posttreatment analysis comparing the MRI/MRSI findings with the PSA levels of 65 patients treated with PPI alone or combined with external beam radiotherapy and/or HT. The fraction of interpretable voxels demonstrating metabolic atrophy was used to compare the TMA with the time to PSA nadir. RESULTS: The fraction of patients with metabolic atrophy in >95% of usable voxels after PPI increased from approximately 46% to 100% at 6 and 48 months, respectively. The mean time for PSA nadir vs. TMA was 42.5 vs. 28.9 months (PPI), 32.8 vs. 25.6 months (external beam radiotherapy + PPI), and 25.3 vs. 28.0 months (external beam radiotherapy + hormonal therapy + PPI). CONCLUSION: Magnetic resonance spectroscopic imaging may provide an early tool for evaluating the treatment response for patients treated with PPI. If supported by longer follow-up, TMA may be a useful adjunct to PSA measurement for assessing local control after PPI and could be useful in evaluating the complex relationships between the quality of the implant and the time to indication of successful therapy.

Brachytherapy↗